joining you everyone Thank for us today.
XXXX. our and year stage we and X a have our look to to discuss our pipeline submitted our We as NDAs from an to transition was completed company exciting commercial topics last of lot X XXXX results a organization. Eton. We XXXX product share successfully a of forward R&D for transformative
completed of liquid months, our with transaction addition, seen In launched and in we oral have a products. products recent two major commercially our
of the treatment I and the only commercial with product, granular use cortical launch is formulation in the Alkindi designed will for for Sprinkle first start Alkindi FDA First, of insufficiency, our Sprinkle. children. lead hydrocortisone specifically approved adrenal
in the January launched promotional in after Although really season. late activities QX, the accelerated holiday product
nurses been Alkindi can and to have community. reception have learn more received young pleased it been have and Our eager sales reps initial the how very Caregivers they from endocrinology and patients. the benefit about Sprinkle physicians with
mostly months. increase meetings those recent welcome the been coming the in While we we seen actually doctors and in have of meetings virtual, weeks, to in-person certain have meetings expect to-date sales rep frequency
been of to we broader “quick of reach with patients have quality a of immediately two to helpful possibly meetings first the short interactions of product. script All the starts. and give even new adoption behind is a these face-to-face this the lead patients in facilitated while physician’s paperwork administrative While of virtual a improved time, are we provided amount their free charge, start,” by will new fill a the pharmacy benefit lag revenue Many means us their or month believe faster where office, payer. may the
the in one don’t Our paperwork number to patients get we to while need wait believe sorted Sprinkle they and should is priority Alkindi have administrative is to being out. the
pace still on months it is early XXXX only are us, by and of we adoption we rates far launch believe are with we we X have full encouraged thus seen While behind plan. our for
increased of is pace every an February. seen show substantial scripts to launch number new patient on over have month since We and March growth
product XXXX. to We to of profit expect approximately throughout and year the XXX the continue positive end patients the on contribution expect by have
we decided patients, Given grow the acquire Canadian to and due the to announced from January. we rights for this which and franchise inbound Alkindi interest Alkindi in to demand physicians and product,
a Health retailers as in working that Eton U.S. Canadian this ophthalmic double-digit major of to royalty payment free approved quickly $X.X allergic launch Alaway and owed announce receive product product product. for as is are the triggered all pleased has on the million into will the secondly possible. a also we We conjunctivitis. The Also Free to bring now patients sales first Preservative Bausch preservative February, to launched
that assets. market a oral have address significant After began these were clear liquid with Azurity ultimately that XXXX, to capitalize and analysis us they our to important it attractive that working as decided in on though for the Pharmaceuticals. neurology Azurity our way how value assembling was with would we and to Next, we to products we thought, on the we discuss patients I’d them. regardless much partnering transaction like of in recently products monetize was announced result, When critical knew most needs
First, it lock allowed our on a to very attractive us return investment. in
years. market product. and receive We successfully us in confidence of these in receive products. a $XX they will products the infrastructure and on oral to in space company be payments the entitled royalties to leader launched million oral up in solutions sales branded milestone to plus liquid still Their is recent experience gives are best the numerous Azurity
you as which key profitability, our priorities. of our boosts it know is one Lastly,
to the acquire In amount XXXX. to in of no be from the orphan in to our the reduced, and additional This products strategy, on longer our need will drastically over launch drug force our profitability expenses sales invest next company’s transaction, and the significant to transaction product drug Eton Azurity allows orphan in addition of improves neurology couple coming associated the expenses. cash effectively us efforts years commercial use the from focus proceeds which because
Alkindi attributes have are are potential, and sales revenue targeted products orphan commercialized similar focused significant force. finding on late meaning needs stage, with indications, that We a for address products to with critical can unmet be
alcohol, set launches review reviews approvals of have XX. XXXX. products In X date commercial under which our product a are us have addition believe FDA regulatory product going A and We the up to should the well, PDUFA FDA. orphan dehydrated that under three for number product, review include exciting few of with additional we products, the May decided of which potential drug is in key are
August $X the with in X. to this believe Zonisamide on oral also engaged to $X of PDUFA sales. and its date owned date. Topiramate communications receive entitled oral August is approved Topiramate product has owned product royalty for trigger product on by of expect date now suspension, X. payment Upon which Eton product’s a we been will which by also will to Azurity PDUFA and is and XX. launch, and review have payment a approval has be track and We the be and also launch approval for million the May we a PDUFA standard FDA the solution, Azurity on million is
As more XXXX, excited we better positioned Eton never it today. could prospects. or has be to than our about look is forward stronger not been I
We – we products have have now three three commercial generating revenue.
under has have are position additional Many expected We of been in be launched six and our better. which products And review. the months. approved financial coming never to
year of would the product sitting becoming We approvals. for are up With cash call open we realize cash with on strong to the to questions. cusp even now expected your and on a in position, profitable come when additional later we like Operator? that, more the
